Novavax, Inc. Share Price Nasdaq
Equities
US6700021040
Biotechnology & Medical Research
Sales 2024 * | 846M 70.5B | Sales 2025 * | 986M 82.25B | Capitalization | 572M 47.73B |
---|---|---|---|---|---|
Net income 2024 * | -112M -9.34B | Net income 2025 * | -90M -7.5B | EV / Sales 2024 * | 0.07 x |
Net cash position 2024 * | 510M 42.56B | Net cash position 2025 * | 482M 40.21B | EV / Sales 2025 * | 0.09 x |
P/E ratio 2024 * |
-5.66
x | P/E ratio 2025 * |
-103
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.33% |
Latest transcript on Novavax, Inc.
Managers | Title | Age | Since |
---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23/23/23 |
John Trizzino
PSD | President | 64 | 10/14/10 |
James Kelly
DFI | Director of Finance/CFO | 58 | 16/21/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 29/22/29 |
Gregg Alton
BRD | Director/Board Member | 58 | 01/20/01 |
David Mott
BRD | Director/Board Member | 58 | 16/20/16 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |